Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Concert Pharmaceuticals
Thumbnail
May 23, 2022

Concert alopecia win rubs Salt in its wounds

Thumbnail
March 31, 2022

Significant readouts for small players

Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.

Article image
Vantage logo
August 04, 2021

Pfizer attacks Lilly’s Jak in alopecia

Article image
Vantage logo
March 03, 2021

Olumiant leads the alopecia Jak pack

Article image
Vantage logo
March 02, 2021

Neurocrine looks for the silver linings in schizophrenia failure

Article image
Vantage logo
September 03, 2019

Concert squares up to Pfizer in alopecia Jak bout

Concert believes that high-dose data with CTP-543 will help it challenge Pfizer, but patent questions still loom large.

Article image
Vantage logo
July 31, 2019

Aclaris’s alopecia Jak might not be worth its Salt

Article image
Vantage logo
June 17, 2019

Incyte hopes its cream can rise to the top

Article image
Vantage logo
April 09, 2019

Concert out of tune after patent stumble

Article image
Vantage logo
February 26, 2019

Xeljanz warning Jaks up safety concerns

An increased risk of blood clots and death with Pfizer’s drug could also bode ill for newer Jak inhibitors.

Article image
Vantage logo
November 12, 2018

Concert’s value shaved after early alopecia win

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up